ArticleJournal of virology1998
Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 268 citations in OpenAlex.
- Enhanced transcriptional insulation of lentiviral vectors using "sequence-upgraded polyA long terminal repeats" or "supA-LTRs".Molecular therapy. Advances · 2026Article
- FromImmune network · 2026Review
- Properties and Application of Pseudotyped Lentiviral Vectors.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Risks of replication-competent retro/lentivirus from associated vector systems: Is it time for a roadmap toward reduced testing?Molecular therapy. Methods & clinical development · 2025Review
- Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Membrane adsorber design for lentiviral vector recovery.Molecular therapy. Methods & clinical development · 2025Article
- Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors.International journal of molecular sciences · 2025Review
- Enhancing titers of therapeutic lentiviral vectors using PKC agonists.Molecular therapy. Methods & clinical development · 2025Article
- RelA and mitogen-activated protein kinase kinase kinases potently enhance lentiviral vector production.Biochemistry and biophysics reports · 2024Article
- Sendai F/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using α 2,3 sialylated receptors.Molecular therapy. Methods & clinical development · 2022Article
- Cancer Gene Therapy: Development and Production of Lentiviral Vectors for Gene Therapy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods.Current medical science · 2021Review
- Recent advances in lentiviral vectors for gene therapy.Science China. Life sciences · 2021Review
- Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.Viruses · 2021Review
- Lentiviral Vector Bioprocessing.Viruses · 2021Review
- Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media.Molecular therapy. Methods & clinical development · 2020Article
- Improved third-generation lentiviral packaging with pLKO.1C vectors.BioTechniques · 2020Article
- Review
- Establishing a dual knock-out cell line by lentivirus based combined CRISPR/Cas9 and Loxp/Cre system.Cytotechnology · 2018Article
- Enhancing titres of therapeutic viral vectors using the transgene repression in vector production (TRiP) system.Nature communications · 2017Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of human immunodeficiency virus vectors for gene therapy is hampered by concern over their safety. This concern might be ameliorated, in part, if the viral accessory genes and proteins could be eliminated from the vector genomes and particles. Here we describe a minimal vector system that is capable of transducing nondividing cells and which does not contain tat, vif, vpr, vpu, and nef.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.